Stiripentol in Dravet Syndrome

NO_LONGER_AVAILABLE

Conditions studied: Dravet Syndrome

In brief

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Key facts

Study ID

NCT01533506

Run by

Mayo Clinic

Starts

2012-02-01

Expected to finish

2013-02-01

Last updated by the study team

2013-02-28

Who can join

Age: 11 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.